Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Tofacitinib is an effective and safe treatment for alopecia areata.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Biosimilars lower costs but don't significantly improve access.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Entospletinib effectively prevents eye and skin GVHD in mice.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.